A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a the researchers launched, single-center, prospective, open-label, single arm ,Phase
II clinical study of Sintilimab combined with anlotinib in patients with extensive-stage
disease small-cell lung cancer to evaluate the efficacy and safety.
23 patients are expected to be enrolled in this study.